drugset / Trial / NCT05075044
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected
Phase 4
Unknown
400 enrolled
China National Biotec Group Company Limited
Hubei Provincial Center for Disease Control and Prevention · collabWuhan Institute of Biological Products Co., Ltd · collab
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity and safety of the subjects aged 18 years and above with HIV-infected recruited to receive three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .
Timeline
- Start
- 2021-10-08
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoronaVac | Vaccine | — | — |